Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Reduced Pro-Inflammatory Cytokines after Eight Weeks of Low-Dose Naltrexone for Fibromyalgia
Luke Parkitny, Jarred Younger
Biomedicines (2017) Vol. 5, Iss. 2, pp. 16-16
Open Access | Times Cited: 88

Showing 1-25 of 88 citing articles:

Inflammation in the pathophysiology of neuropathic pain
Claudia Sommer, Mathias Leinders, Nurcan Üçeyler
Pain (2017) Vol. 159, Iss. 3, pp. 595-602
Closed Access | Times Cited: 397
Microglia polarization in nociplastic pain: mechanisms and perspectives
Ahd A. Atta, Weam W. Ibrahim, Ahmed F. Mohamed, et al.
Inflammopharmacology (2023) Vol. 31, Iss. 3, pp. 1053-1067
Open Access | Times Cited: 63
Low-Dose Naltrexone (LDN)—Review of Therapeutic Utilization
Karlo Toljan, Bruce Vrooman
Medical Sciences (2018) Vol. 6, Iss. 4, pp. 82-82
Open Access | Times Cited: 120
Role of inflammation in the pathogenesis and treatment of fibromyalgia
İlke Coşkun Benlidayı
Rheumatology International (2019) Vol. 39, Iss. 5, pp. 781-791
Closed Access | Times Cited: 120
The Safety and Efficacy of Low‐Dose Naltrexone in the Management of Chronic Pain and Inflammation in Multiple Sclerosis, Fibromyalgia, Crohn's Disease, and Other Chronic Pain Disorders
Denise K. Patten, Bob G. Schultz, Daniel J. Berlau
Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy (2018) Vol. 38, Iss. 3, pp. 382-389
Open Access | Times Cited: 111
Pain Biomarkers in Fibromyalgia Syndrome: Current Understanding and Future Directions
Martina Favretti, Cristina Iannuccelli, Manuela Di Franco
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 13, pp. 10443-10443
Open Access | Times Cited: 24
Low-dose naltrexone and NAD+ for the treatment of patients with persistent fatigue symptoms after COVID-19
Anar Isman, Andy Nyquist, Bailey Strecker, et al.
Brain Behavior & Immunity - Health (2024) Vol. 36, pp. 100733-100733
Open Access | Times Cited: 14
Low-dose naltrexone (LDN): A promising treatment in immune-related diseases and cancer therapy
Zijian Li, Yue You, Noreen Griffin, et al.
International Immunopharmacology (2018) Vol. 61, pp. 178-184
Closed Access | Times Cited: 70
Low-Dose Naltrexone for Chronic Pain: Update and Systemic Review
Phillip S. Kim, Michael Fishman
Current Pain and Headache Reports (2020) Vol. 24, Iss. 10
Closed Access | Times Cited: 56
Low-dose naltrexone inhibits colorectal cancer progression and promotes apoptosis by increasing M1-type macrophages and activating the Bax/Bcl-2/caspase-3/PARP pathway
Mingxing Ma, Xiaonan Wang, Ning Liu, et al.
International Immunopharmacology (2020) Vol. 83, pp. 106388-106388
Closed Access | Times Cited: 51
Cancer Metabolism as a Therapeutic Target and Review of Interventions
Matthew Halma, Jack A. Tuszyński, Paul E. Marik
Nutrients (2023) Vol. 15, Iss. 19, pp. 4245-4245
Open Access | Times Cited: 19
The Safety and Efficacy of Low-Dose Naltrexone in Patients with Fibromyalgia: A Systematic Review
Juan Yang, Kyung-Min Shin, Alex Do, et al.
Journal of Pain Research (2023) Vol. Volume 16, pp. 1017-1023
Open Access | Times Cited: 16
Immunometabolic Modulatory Role of Naltrexone in BV-2 Microglia Cells
Natalia Kučić, Valentino Rački, Roberta Šverko, et al.
International Journal of Molecular Sciences (2021) Vol. 22, Iss. 16, pp. 8429-8429
Open Access | Times Cited: 34
Is Fibromyalgia a Fashionable Diagnosis or a Medical Mystery?
Giustino Varrassi, Martina Rekatsina, Serge Perrot, et al.
Cureus (2023)
Open Access | Times Cited: 14
Effect of Naltrexone on Spinal and Supraspinal Pain Mechanisms and Functional Capacity in Women with Fibromyalgia: Exploratory Outcomes from the Randomized Placebo-Controlled FINAL Trial
Karin Due Bruun, Robin Christensen, Kirstine Amris, et al.
CNS Drugs (2025)
Open Access
Pharmacology Update: Low-Dose Naltrexone as a Possible Nonopioid Modality for Some Chronic, Nonmalignant Pain Syndromes
Diana Trofimovitch, Steven J. Baumrucker
American Journal of Hospice and Palliative Medicine® (2019) Vol. 36, Iss. 10, pp. 907-912
Closed Access | Times Cited: 42
Featured Article: Serum [Met5]-enkephalin levels are reduced in multiple sclerosis and restored by low-dose naltrexone
Michael D Ludwig, Ian S. Zagon, Patricia J. McLaughlin
Experimental Biology and Medicine (2017) Vol. 242, Iss. 15, pp. 1524-1533
Open Access | Times Cited: 41
Successful treatment of postural orthostatic tachycardia and mast cell activation syndromes using naltrexone, immunoglobulin and antibiotic treatment
Leonard B. Weinstock, Jill Brook, Trisha L Myers, et al.
BMJ Case Reports (2018), pp. bcr-221405
Open Access | Times Cited: 39
Potential Therapeutic Benefit of Low Dose Naltrexone in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome: Role of Transient Receptor Potential Melastatin 3 Ion Channels in Pathophysiology and Treatment
Hélène Cabanas, Katsuhiko Muraki, Natalie Eaton-Fitch, et al.
Frontiers in Immunology (2021) Vol. 12
Open Access | Times Cited: 29
Efficacy of Low-Dose Naltrexone and Predictors of Treatment Success or Discontinuation in Fibromyalgia and Other Chronic Pain Conditions: A Fourteen-Year, Enterprise-Wide Retrospective Analysis
Christine Driver, Ryan S. D’Souza
Biomedicines (2023) Vol. 11, Iss. 4, pp. 1087-1087
Open Access | Times Cited: 11
Naltrexone a potential therapeutic candidate for COVID-19
Abhinav Choubey, Budheswar Dehury, Sunil Kumar, et al.
Journal of Biomolecular Structure and Dynamics (2020) Vol. 40, Iss. 3, pp. 963-970
Open Access | Times Cited: 29
Low-dose naltrexone’s utility for non-cancer centralized pain conditions: a scoping review
Adam Rupp, Erin E. Young, Andrea L. Chadwick
Pain Medicine (2023) Vol. 24, Iss. 11, pp. 1270-1281
Open Access | Times Cited: 10
Low-dose naltrexone in the treatment of myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS)
Olli Polo, Pia Pesonen, Essi Tuominen
Fatigue Biomedicine Health & Behavior (2019) Vol. 7, Iss. 4, pp. 207-217
Open Access | Times Cited: 26
Naltrexone (NTX) relieves inflammation in the collagen-induced- arthritis (CIA) rat models through regulating TLR4/NFκB signaling pathway
Neili Xu, Yuejiao Wang, Shuai Zhao, et al.
International Immunopharmacology (2019) Vol. 79, pp. 106056-106056
Open Access | Times Cited: 26
The Influence of Pro-inflammatory Cytokines and Genetic Variants in the Development of Fibromyalgia: A Traditional Review
Mercedes Maria Peck, Ruchira Maram, Alaa A. Mohamed, et al.
Cureus (2020)
Open Access | Times Cited: 25
Page 1 - Next Page

Scroll to top